Skip to main content


Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

Grant Details

Grant Number: 3R01CA071358-04S1 Interpret this number
Primary Investigator: Swan, Gary
Organization: Sri International
Project Title: Treatment of Nicotine Dependence in an Hmo Setting
Fiscal Year: 2002
Back to top


DESCRIPTION: In the grant CA71358, Treatment of Nicotine Dependence in and HMO Setting, we conducted a large randomized field trial of the effectiveness of two different doses of bupropion SR (150mg or 300mg) in combination with two different approaches to behavioral support (the Zyban Advantage Plan (ZAP), a personalized mailing program or Free & Clear, a proactive telephone-based smoking cessation program). The trial, conducted at Group Health Cooperative (GHC), showed that the higher dose was associated with short-term outcome (similar to the one industry-sponsored trial of different dosing levels) but that higher intensity behavioral counseling was associated with long-term effectiveness. The trial was limited to patients enrolled in the staff model system at GHC and did not include patients under the care of physicians in the GHC "network" - community doctors, group practices, and other hospitals contracted with GHC. In this application we seek to disseminate to 500-700 "networked" providers within GHC Northwest District three main study findings: 1) that a relatively stand-alone recruitment and screening system with physician back-up can result in safe and effective treatment of their smoking patients; 2) that a higher dose of bupropion SR was effective in the short run but more so in combination with the moderately intensive Free & Clear program and that even the lower dose of buproprion SR in combination with Free & Clear program can result in satisfactory outcomes at 12 months; and 3) that encouraging concomitant use of a behavioral support program is a more effective addition to a course of bupropion SR than simply using a higher dose. As part of this dissemination effort we aim to: 1) provide feedback to the targeted populations from the original trial (smokers, GHC staff model physicians); and 2) disseminate the findings from the trial to GHC-contracted physicians and health care providers who were not actively informed while it was being conducted (the "network" physicians) by: a) utilizing components of the Precede-Proceed Model of Health Promotion Planning to devise, in collaboration with the intended audience, an approach to dissemination of the trial's findings and methods that will maximize use of available GHC resources; b) utilizing the theoretical framework provided by Moulding, Silagy and Weller for designing effective dissemination practices; and c) assessing process and outcome measures including elements of the RE-AIM model of Glasgow, Vogt, and Boles to evaluate the dissemination effort. Effective dissemination of the trial's findings will result in greater utilization of behavioral counseling and possibly lower dosages of bupropion SR in the treatment of smokers at GHC. Thus, more efficient use of existing resources will result in greater reach of cessation efforts to smoking patients.

Back to top


None. See parent grant details.

Back to Top